KEY TAKEAWAYS
- This clinical study evaluated the efficacy of an emollient PLUS balm containing ADE-G1 for xerotic cancer patients.
- Emollient+balm with ADE-G1 and education’s efficacy for severe drug-induced xerosis in adult cancer patients were assessed.
- The investigator and patients were assessed at baseline and one month for body xerosis severity, a target xerosis area, subjective signs, the impact of the patient’s skin condition on their quality of life, and overall tolerance.
- The emollient PLUS balm containing ADE-G1 showed a significant benefit versus the real-life control group in xerotic cancer pts.
In this multi-center study, xerotic patients treated with systemic anticancer drugs were randomly assigned to two parallel groups. The treated group applied the emollient PLUS balm containing Aquaphilus dolomiae extract (ADE-G1) twice daily and received education to support their treatment. On the other hand, the controlled group proposed the best supportive care at the physicians’ discretion, and then the study product and education if there was insufficient improvement after four weeks (cross-over). The investigator and patients were assessed at baseline and one month for both groups regarding global body xerosis severity, a target xerosis area, subjective signs, the impact of the patient’s skin condition on their quality of life, and overall tolerance. Additionally, instrumental evaluation was conducted by corneometer and Dsquam quantification. After that, statistical inter-group analysis was carried out on principal and secondary criteria.
The research comprised 29 adults, with 15 receiving treatment and the rest, 14, acting as the control group. The analysis between baseline and the end of the treatment phase in the treated group showed a significant improvement in both global body xerosis severity and in the target area. The DLQI score also improved at the end of the follow-up, with a reduction of 57% in the treated group. Furthermore, the hydration index and Dsquam quantification showed substantial improvements. The study product showed good tolerance and acceptance by the patients.
The results of this randomized controlled clinical study supported the use of the emollient PLUS balm containing ADE-G1 for xerotic cancer patients. This treatment and the educational program revealed a significant benefit compared to the real-life control group. These findings suggest that this treatment option could be a valuable addition to those with xerotic cancer care.
Source: https://eado2023.com/wp-content/uploads/2023/04/Abstract-Band_EADO2023_Stand-21-04-2023-kl.pdf
Clinical Trial: https://classic.clinicaltrials.gov/ct2/show/NCT04181177
Pr NICOLAS MEYER, Pr Brigitte Dreno, PhD Amir Khammari, Dr FLORIAN DEILHES, Dr VINCENT SIBAUD, Dr C. UTHURRIAGUE, Dr ELIZABETH DURBISE, Dr FLORENCE AMELOT, JENNYFER LOUSTAU, CHRISTOPHE LAUZE, ADELINE BACQUEY, ALINE STENNEVIN, Dr ELEONORA CINELLI, PhD PIERRE-JACQUES FERRET, Dr THERESE NOCERA 1 PIERRE FABRE DERMOCOSMETIQUE and PERSONAL CARE RESEARCH AND DEVELOPMENT DEPARTMENT / 2 rue Viguerie 31000 Toulouse, France
